Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Kaitai Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 98
Average round size
info
The average size of a deal this fund participated in
$12M
Portfolio companies 79
Rounds per year 6.53
Lead investments 19
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Exits 4
Key employees 1
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Artificial Intelligence
Summary

Kaitai Capital is the famous VC, which was founded in 2009. The venture was found in Asia in China. The leading representative office of defined VC is situated in the Hangzhou.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Kaitai Capital, startups are often financed by Viva BioInnovator, TF Capital, Nanjing Jiangbei New District Service Trade Innovation Development Fund. The meaningful sponsors for the fund in investment in the same round are ZGC Group, Xiamen Meiya Wutong Investment Management, Tekla Capital Management. In the next rounds fund is usually obtained by Vertex Ventures China, Source Code Capital, Photon Fund.

The high activity for fund was in 2018. The real fund results show that this VC is 48 percentage points more often commits exit comparing to other companies. The fund is constantly included in 2-6 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Among the most successful fund investment fields, there are Therapeutics, Pharmaceutical. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline CARsgen Therapeutics, Amphivena Therapeutics, Tekeluo Biotech For fund there is a match between the location of its establishment and the land of its numerous investments - China. The fund has exact preference in some founders of portfolio startups.

Besides them, we counted 1 critical employee of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Kaitai Capital:
Typical Co-investors
Kaitai Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Kaitai Capital:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Nafi Pharmaceuticals

Biotechnology
Health Care
Medical
21 Sep 2023 Shenzhen, Guangdong, China

Huaboron Neutron

Biotechnology
Therapeutics
$15M02 Aug 2023 Hangzhou, Zhejiang, China

Levinthal

Artificial Intelligence
Biotechnology
Product Design
$1K27 Jul 2023 Hangzhou, Zhejiang, China

Chiplego

Manufacturing
Semiconductor
19 Jun 2023 Shanghai, Shanghai, China

Xihu Xinchen

Artificial Intelligence
Consulting
Health Care
27 Mar 2023 Hangzhou, Zhejiang, China

ONL Therapeutics

Biotechnology
Pharmaceutical
Therapeutics
$15M08 Mar 2023 Ann Arbor, Michigan, United States

Rgenta Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$52M29 Nov 2022 Cambridge, Massachusetts, United States

Realibox

3D Technology
Cloud Infrastructure
Web Design
$15M26 Sep 2022 Guangzhou, Guangdong, China

Worg Pharmaceuticals

Biotechnology
$61M14 Sep 2022 Shangcheng District, Zhejiang, China
News
Teon Therapeutics Completes $30 Million Series A Financing

– Teon Therapeutics completed a $30m Series A financing.
– The financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives.
– All existing investors also participated in the financing round including Northern Light Venture Capital, Kaitai Capital and Oriental Fortune Capital.
– The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Kaitai Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 98
Average round size 12M
Rounds per year 6.53
Peak activity year 2022
Lead investments 19
Follow on index 0.18
Exits 4
Group Appearance index 0.74

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Nafi Pharmaceuticals

Biotechnology
Health Care
Medical
21 Sep 2023 Shenzhen, Guangdong, China

Huaboron Neutron

Biotechnology
Therapeutics
$15M02 Aug 2023 Hangzhou, Zhejiang, China

Levinthal

Artificial Intelligence
Biotechnology
Product Design
$1K27 Jul 2023 Hangzhou, Zhejiang, China

Chiplego

Manufacturing
Semiconductor
19 Jun 2023 Shanghai, Shanghai, China

Xihu Xinchen

Artificial Intelligence
Consulting
Health Care
27 Mar 2023 Hangzhou, Zhejiang, China

ONL Therapeutics

Biotechnology
Pharmaceutical
Therapeutics
$15M08 Mar 2023 Ann Arbor, Michigan, United States

Rgenta Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
$52M29 Nov 2022 Cambridge, Massachusetts, United States

Realibox

3D Technology
Cloud Infrastructure
Web Design
$15M26 Sep 2022 Guangzhou, Guangdong, China

Worg Pharmaceuticals

Biotechnology
$61M14 Sep 2022 Shangcheng District, Zhejiang, China
Crunchbase icon

Content report

The following text will be sent to our editors: